News and Events
Cell Bridge Strategies Partners with leanRAQA to Create and Implement Unique Life Sciences Go-To-Market Solutions
Merging science, regulation, and business into strategies for success
Boerne, TX. October 5, 2021 — Jane Andrews, PhD, Founder & CEO of Cell Bridge Strategies, LLC has partnered with Michelle Lott, RAC, Principal & Founder of leanRAQA, to add more depth to the regulatory affairs and quality management system expertise offered to their customers.
Cell Bridge Strategies, a global growth consulting firm helps executives and investors in the life sciences, regenerative medicine, cell, and the cell-gene therapies industries to identify and create growth opportunities in domestic and international markets.
Dr. Andrews, CEO of Cell Bridge Strategies has more than 25 years of life science, regenerative medicine, cell therapy and business experience. Based on client’s unique needs, the Cell Bridge Strategies’ team of industry experts deliver customized solutions for science & technologies, operations, and corresponding markets opportunities. “The combination of expertise in science, commercialization and business strategies helps national and international clients successfully launch products, increase valuation and grow revenue streams,” noted Dr. Andrews.
Cell Bridge Strategies delivers insights that help companies match their core assets to optimal growth opportunities and to provide executive and operational support when needed. “Michelle Lott’s expertise in the global regulatory environment adds further depth to Cell Bridge Strategies’ consulting services and better supports clients with regulatory insights to complement our in-house CMC, scientific and business acumen,” said Dr. Andrews.
Michelle Lott has more than twenty years’ experience in regulatory affairs, compliance, quality management, due diligence, and audit support. leanRAQA specializes in supporting life science startups through the development and implementation of quality management systems and completion of regulatory submissions. Since founding leanRAQA in 2010, Michelle has successfully guided more than 100 companies through byzantine regulatory landscapes and on product commercialization success. Michelle has demonstrated time and again that companies can gain a competitive advantage by fully integrating regulatory affairs into their business strategies, and her client’s success is testimony to the validity of that approach.
According to Michelle Lott, “Joining the Cell Bridge Strategies team is a key strategic growth initiative for leanRAQA, where both companies can expand their reach, allowing companies to achieve market entry, build strategies, focus operations and attain regulatory submissions and quality system remediation peace of mind.”
About Cell Bridge Strategies
Cell Bridge Strategies, LLC is a global growth consulting firm that helps executives and investors in life sciences, regenerative medicine, cell, and the cell-gene therapies. Cell Bridge Strategies has the deep understanding of the technologies, products, global regulatory environments, markets, operations, and US and international growth opportunities to help companies advance their products, increase valuation while building their revenue streams. Cell Bridge Strategies delivers insights that help companies match their core assets to the optimal growth opportunities. Our comprehensive consulting services spans R&D, clinical, regulatory, financial and commercial strategies. Learn more at www.cellbridgestrategies.com/
About leanRAQA
Since 2010, 𝗹𝗲𝗮𝗻𝗥𝗔𝗤𝗔 has been on a mission, helping life science and medical device startups merge regulatory and business into successful commercialization strategies. leanRAQA specializes in providing simple solutions to complex regulatory problems - regulatory strategy and planning, submissions, audit preparation and remediation, due diligence, quality systems, compliance and more. Learn more at www.leanraqa.com/